Audentes Therapeutics (BOLD) Announces Update on ASPIRO Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy

Audentes Therapeutics (BOLD) PT Raised to $32 at Evercore ISI

Evercore ISI raised its price target on Audentes Therapeutics (NASDAQ: BOLD) to $32.00 (from $30.00) while maintaining a In Line rating.

Audentes Therapeutics (BOLD) Misses Q2 EPS by 7c

Audentes Therapeutics (NASDAQ: BOLD) reported Q2 EPS of ($0.85), $0.07 worse than the analyst estimate of ($0.78).

"We're very pleased with continued clinical progress in ASPIRO, and in particular the results of the muscle biopsy data from the first three ASPIRO patients, which show unprecedented levels of tissue transduction and protein expression... More